Paper26537178
Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.
Peng L and 4 others. Eur J Cancer Care (Engl), 2017. Cited by 46 papers, by iCite.
Cite this record
ConductScience Library. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Papers, record 26537178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26537178
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Albumins | Major topic |
| Antineoplastic Agents | Major topic |
| Neoplasms | Major topic |
| Paclitaxel | Major topic |
| Peripheral Nervous System Diseases | Major topic |
| Humans | |
| Incidence | |
| Risk | |
| Severity of Illness Index | |
| Taxoids |
Source PubMed
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42439657 | Albumin-Based Drug Delivery for Glioblastoma Treatment: Mechanistic Rationale, Preclinical Evidence, and Clinical Translation. | Cells | 2026 | https://conductscience.org/library/papers/42439657 | PubMed |
| 41840368 | Platinum-free triplet therapy with nab-paclitaxel, S-1, and tislelizumab as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma: a phase ii single-arm trial. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41840368 | PubMed |
| 40819029 | Nab-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as first-line treatment in advanced biliary tract cancer: results of a multicentre, randomised, phase II trial. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40819029 | PubMed |
| 40230322 | Comparison of nab-paclitaxel, paclitaxel, and oxaliplatin-induced peripheral neuro-pathy: a cross-sectional cohort study. | Acta Oncol | 2025 | https://conductscience.org/library/papers/40230322 | PubMed |
| 39589666 | Safety and efficacy of generic nab-paclitaxel-based therapy in Chinese patients with malignant tumors in a real-world setting: a multicenter prospective observational study. | Discov Oncol | 2024 | https://conductscience.org/library/papers/39589666 | PubMed |
| 39403794 | Chemotherapy-induced cognitive impairment and its long-term development in patients with breast cancer: results from the observational CICARO study. | Oncologist | 2025 | https://conductscience.org/library/papers/39403794 | PubMed |
| 37403746 | Effectiveness, safety, and impact on quality of life of eribulin-based therapy in heavily pretreated patients with metastatic breast cancer: A real-world analysis. | Cancer Med | 2023 | https://conductscience.org/library/papers/37403746 | PubMed |
| 37270638 | A retrospect study based on real-world data to observe metabolic function in cancer patients using albumin-bound paclitaxel. | Sci Rep | 2023 | https://conductscience.org/library/papers/37270638 | PubMed |
| 36675434 | A Prospective, Randomized, Placebo-Controlled Study Assessing the Efficacy of Chinese Herbal Medicine (Huangqi Guizhi Wuwu Decoction) in the Treatment of Albumin-Bound Paclitaxel-Induced Peripheral Neuropathy. | J Clin Med | 2023 | https://conductscience.org/library/papers/36675434 | PubMed |
| 36147633 | Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer. | Biomed Res Int | 2022 | https://conductscience.org/library/papers/36147633 | PubMed |
| 35614037 | Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions. | Cell Death Dis | 2022 | https://conductscience.org/library/papers/35614037 | PubMed |
| 35141015 | 5-arylalkynyl-2-benzoyl thiophene: a novel microtubule inhibitor exhibits antitumor activity without neurological toxicity. | Am J Cancer Res | 2022 | https://conductscience.org/library/papers/35141015 | PubMed |
| 34655433 | Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment. | Oncol Ther | 2021 | https://conductscience.org/library/papers/34655433 | PubMed |
| 34481421 | Mechanistic insights into the pathogenesis of microtubule-targeting agent-induced peripheral neuropathy from pharmacogenetic and functional studies. | Basic Clin Pharmacol Toxicol | 2022 | https://conductscience.org/library/papers/34481421 | PubMed |
| 33922821 | Association between Low-Grade Chemotherapy-Induced Peripheral Neuropathy (CINP) and Survival in Patients with Metastatic Adenocarcinoma of the Pancreas. | J Clin Med | 2021 | https://conductscience.org/library/papers/33922821 | PubMed |
| 33671327 | Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33671327 | PubMed |
| 33445874 | The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors. | Chem Rev | 2021 | https://conductscience.org/library/papers/33445874 | PubMed |
| 33370027 | Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. | Pancreas | 2021 | https://conductscience.org/library/papers/33370027 | PubMed |
| 31901783 | Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial. | Breast | 2020 | https://conductscience.org/library/papers/31901783 | PubMed |
| 31592123 | Immunotoxicity Considerations for Next Generation Cancer Nanomedicines. | Adv Sci (Weinh) | 2019 | https://conductscience.org/library/papers/31592123 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26537178
GET https://conductscience.org/api/papers/v1/26537178/cited_by?page=2